Emerging role of NLRP3 inflammasome as a therapeutic target in cardiovascular and infectious diseases

  • Chair(s):

    Na Li,
    Assistant Professor,Department of Medicine, Baylor College of Medicine, Houston, TX, The United States of America

    Shigeki Miyamoto,
    Associate Professor,Department of Pharmacology, University of Califonia - San Diego, San Diego, CA, The United States of America

  • Session description:

    Targeting the NLRP3 inflammasome for the treatment of inflammatory diseases
    Dr Rebecca Coll
    Lecturer in Immunobiology, Queen’s University Belfast, Belfast, United Kingdom

    CaMKII signaling and NLRP3 inflammasome activation in cardiomyocyte mediated inflammation
    Professor Shigeki Miyamoto
    Associate Professor, Department of Pharmacology University of California, San Diego, San Diego, CA, The United States of America

    Oral communication speaker - to be confirmed in 2023.

    Pathological role of NLRP3 inflammasome in the development of atrial fibrillation
    Dr Marcel Tekook
    Department of Pharmacology, University of Duisburg – Essen Germany, Essen, Germany

    Inflammasome activation and COVID-19 patients
    Stefano Toldo Assistant Professor of Medicine, Department of Internal Medicine, Virginia Commonwealth University, Virginia, USA

  • 00


  • 00


  • 00


  • 00



03 Jul 2023


4:05 pm - 6:30 pm


Leave A Comment

Go to Top